Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of the American College of Cardiology

• Publication date

  2008-08-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2008.05.022PMID 18702968
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2009cited by this paper
• Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure.

  2008cited by this paper
• Genetic Variation Within the β1-Adrenergic Receptor Gene Results in Haplotype-Specific Expression Phenotypes

  2008cited by this paper
• Role of β adrenergic receptor polymorphisms in heart failure: Systematic review and meta‐analysis

  2008cited by this paper
• The year in heart failure.

  2007cited by this paper
• Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure.

  2007cited by this paper
• Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study.

  2007cited by this paper
• Pharmacogenetics of beta-blockers.

  2007cited by this paper
• Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2007cited by this paper
• Relation of β2-Adrenoceptor Haplotype to Risk of Death and Heart Transplantation in Patients With Heart Failure

  2007cited by this paper
• Pharmacogenetics of β‐Blockers

  2007cited by this paper
• The Seattle Heart Failure Model: Prediction of Survival in Heart Failure

  2006cited by this paper
• Redefining heart failure: the utility of genomics.

  2006cited by this paper
• A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

  2006cited by this paper
• Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study.

  2006cited by this paper
• A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure

  2006cited by this paper
• b1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to b-blocker therapy

  2005cited by this paper
• Mechanisms of Disease: β-adrenergic receptors—alterations in signal transduction and pharmacogenomics in heart failure

  2005cited by this paper
• The impact of beta‐adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure *

  2005cited by this paper
• Genetic causes of human heart failure.

  2005cited by this paper
• Heart failure

  2005cited by this paper
• β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure

  2005cited by this paper
• Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure

  2005cited by this paper
• Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects.

  2004cited by this paper
• β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

  2003cited by this paper
• Beta-adrenoceptor genotype influences the response to carvedilol in patients with congestive heart failure.

  2003cited by this paper
• An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study

  2003cited by this paper
• Pharmacology and physiology of human adrenergic receptor polymorphisms.

  2003cited by this paper
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study

  2002cited by this paper
• Pharmacogenetics of Beta-1- and Beta-2-Adrenergic Receptors

  2000cited by this paper
• A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor*

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper

  1977cited by this paper
• Heart Failure

  1937cited by this paper

• β1- and β2-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol

  2025cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy

  2024cites this paper
• Non‑synonymous polymorphisms in the HRC and ADRB1 genes may be associated with all‑cause death in patients with non‑ischemic heart failure

  2023cites this paper
• Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers

  2021cites this paper
• Genetic Polymorphisms in ADRB2 and ADRB1 Are Associated with Differential Survival in Heart Failure Patients Taking β-Blockers

  2021cites this paper
• Adrenergic Receptor Signaling in Heart Failure

  2020cites this paper
• Adrenergic Polymorphisms and Survival in African Americans With Heart Failure: Results From A-HeFT.

  2019cites this paper
• GENETIC-AF: Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined Heart Failure Population.

  2019cites this paper
• Pharmacogenetics in Cardiovascular Diseases

  2019cites this paper
• Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

  2019cites this paper
• Withstanding the flow: Human cardiovascular control during postural challenges

  2018cites this paper
• Cardiovascular Receptors and Signaling in Heart Failure

  2018cites this paper
• Dose Response of &bgr;-Blockers in Adrenergic Receptor Polymorphism Genotypes

  2018cites this paper
• ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure

  2018cites this paper
• Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

  2017cites this paper
• Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity.

  2017cites this paper
• A genotype‐directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC‐AF trial

  2017cites this paper
• Pharmacogenomics of heart failure: a systematic review.

  2016cites this paper
• Association between Beta1‐Adrenergic Receptor Polymorphism and Risk of ICD Shock in Heart Failure Patients

  2016cites this paper
• Beta-blockers in COPD: time for reappraisal

  2016cites this paper
• Practical Pharmacogenomic Approaches to Heart Failure Therapeutics

  2016cites this paper
• The Gly16 Allele of the Gly16Arg Single-Nucleotide Polymorphism in the &bgr;2-Adrenergic Receptor Gene Augments Perioperative Use of Vasopressors: A Retrospective Cohort Study

  2016cites this paper
• Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease

  2016cites this paper
• Cardiovascular Pharmacogenomics – Implications for Patients with Chronic Kidney Disease

  2016cites this paper
• Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

  2016cites this paper
• Beta Adrenergic Receptors

  2015cites this paper
• Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure

  2015cites this paper
• Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure

  2015cites this paper
• Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.

  2015cites this paper
• Genetic Variants Are Not Associated with Outcome in Patients with Coronary Artery Disease and Left Ventricular Dysfunction: Results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) Trials

  2015cites this paper
• Pharmacogenomics of Hypertension and Heart Disease

  2015cites this paper
• A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience

  2015cites this paper
• Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.

  2015cites this paper
• The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure

  2015cites this paper
• Pharmacogenomics in Heart Failure: Where Are We Now and How Can We Reach Clinical Application?

  2014cites this paper
• Polymorphic Variants of Adrenoceptors: Pharmacology, Physiology, and Role in Disease

  2014cites this paper
• Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy

  2014cites this paper
• Pharmacogenetics in Cardiovascular Disease: The Challenge of Moving From Promise to Realization

  2014cites this paper
• The impact of β 2 adrenergic receptor polymorphisms on the outcomes in cardiovascular diseases

  2014cites this paper
• Common α2A and α2C adrenergic receptor polymorphisms do not affect plasma membrane trafficking

  2014cites this paper
• GNAS Gene Variants Affect &bgr;-blocker–related Survival after Coronary Artery Bypass Grafting

  2014cites this paper
• Pharmacogenomics of heart failure.

  2014cites this paper
• Race, common genetic variation, and therapeutic response disparities in heart failure.

  2014cites this paper
• Pharmacogenetics of cardiac inotropy.

  2014cites this paper
• Alpha-1–Adrenergic Receptors in Heart Failure: The Adaptive Arm of the Cardiac Response to Chronic Catecholamine Stimulation

  2014cites this paper
• Polymorphisms and Treatment- Outcomes in Cardiovascular

  2013cites this paper
• Biomarker-guided therapies in heart failure: a forum for unified strategies.

  2013cites this paper
• Adrenergic Nervous System in Heart Failure: Pathophysiology and Therapy

  2013cites this paper
• Differential Effects of Nonselective Versus Selective β-Blockers on Cardiac Sympathetic Activity and Hemostasis in Patients with Heart Failure

  2013cites this paper
• Pharmacogenetics of ò1-Adrenergic Receptor Blockers in Heart FailureTherapy: A Systematic Review

  2013influential citation
• Pharmacogenetics of β1-Adrenergic Receptor Blockers in Heart Failure Therapy: A Systematic Review

  2013influential citation
• Pharmacogenomics and heart failure in congenital heart disease.

  2013cites this paper
• Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias With Bucindolol in Patients With Chronic Heart Failure

  2013cites this paper
• B2 Adrenergic Receptor Polymorphisms and Treatment- Outcomes in CardiovascularDiseases

  2013cites this paper
• Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation

  2013cites this paper
• Genetic Prediction of Heart Failure Incidence, Prognosis and Beta-blocker Response

  2013cites this paper
• Interactions between Social/ behavioral factors and ADRB2 genotypes may be associated with health at advanced ages in China

  2013cites this paper
• Association between adrenergic receptor genotypes and beta‐blocker dose in heart failure patients: analysis from the HF‐ACTION DNA substudy

  2013cites this paper
• Pharmacogenetics in Chronic Heart Failure: New Developments and Current Challenges

  2012cites this paper
• Impact of synergistic polymorphisms in adrenergic receptor-related genes and cardiovascular events in patients with dilated cardiomyopathy.

  2012cites this paper
• Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.

  2012cites this paper
• Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

  2012cites this paper
• Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.

  2012cites this paper
• Pharmacogenetics and anaesthesia: the value of genetic profiling

  2012cites this paper
• A Case for Pharmacogenomics in Management of Cardiac Arrhythmias

  2012cites this paper
• Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors.

  2012cites this paper
• Genetic determinants of response to cardiovascular drugs

  2012cites this paper
• Pharmacogenetic targeting of drugs for heart failure.

  2012cites this paper
• The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure

  2012influential citation
• Pharmacogenetics of Drug Targets

  2012cites this paper
• Chapter 45 – Adrenergic Receptor Polymorphisms in Heart Failure

  2012cites this paper
• Intérêt de la variabilité du rythme cardiaque comme marqueur de risque

  2012cites this paper
• Systems-based approaches to cardiovascular disease

  2012cites this paper
• Clinical application of cardiovascular pharmacogenetics.

  2012cites this paper
• Pharmacogenomics: The Genetics of Variable Drug Responses

  2011cites this paper
• The Genomic Architecture of Sporadic Heart Failure

  2011cites this paper
• The genomic architecture of sporadic heart failure.

  2011cites this paper
• Genetic interactions in the β-adrenoceptor/G-protein signal transduction pathway and survival after coronary artery bypass grafting: a pilot study.

  2011cites this paper
• Cardiovascular Pharmacogenomics of Adrenergic Receptor Signaling: Clinical Implications and Future Directions

  2011cites this paper
• Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.

  2011cites this paper
• Genetic variation, β-blockers, and perioperative myocardial infarction.

  2011cites this paper
• Treatment of chronic heart failure with β-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology.

  2011cites this paper
• Polymorphisms of the Beta Adrenergic Receptor Predict Left Ventricular Remodeling Following Acute Myocardial Infarction

  2011cites this paper
• β2-adrenergic receptor genotype influences the effect of nonselective vs. selective β-blockade on baroreflex function in chronic heart failure.

  2011cites this paper
• Future of personalized pharmacotherapy in chronic heart failure patients.

  2011cites this paper
• Chapter 46 – Antagonism of the Sympathetic Nervous System in Heart Failure

  2011cites this paper
• Chapter 42 – Pharmacogenomics and Pharmacogenetics in Heart Failure

  2011cites this paper
• Genetics Primer for the General Cardiologist Pharmacogenomics The Genetics of Variable Drug Responses

  2011cites this paper
• Genetics Primer for the General Cardiologist

  2011cites this paper
• Bucindolol: A Pharmacogenomic Perspective on Its Use in Chronic Heart Failure

  2011cites this paper
• Progression of Left Ventricular Dysfunction and Remodelling under Optimal Medical Therapy in CHF Patients: Role of Individual Genetic Background

  2011cites this paper
• Chapter 10 – Activation of the Adrenergic Nervous System in Heart Failure

  2011cites this paper
• The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart

  2011cites this paper
• Β-arrestin: a signaling molecule and potential therapeutic target for heart failure.

  2011cites this paper
• Cardiovascular pharmacogenomics.

  2011cites this paper
• Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.

  2011cites this paper
• Heart Failure Pharmacogenetics: Past, Present, and Future

  2011influential citation
• Pharmacogenetics in heart failure trials.

  2011cites this paper
• Role of β-blocker therapy in pediatric heart failure.

  2010cites this paper
• RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

  2010cites this paper